Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPO
A secretive biotech out of Wilmington, DE, closed a massive, nine-figure Series C on Wednesday, and it comes from an investor syndicate that is highly indicative of IPO preparations.
NiKang Therapeutics secured $200 million in its latest funding round, the company announced, bringing blue-chip investors such as RA Capital Management, Perceptive, Cormorant Asset Management and Ecor1 into the fold. The round comes about a month and a half after NiKang appointed a new chief financial officer in Kelsey Chen, formerly a managing director at Cormorant.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.